Saatja: Biviano, Florencia <
[email protected]>
Saadetud: 27.09.2019 12:46
Adressaat: Elen Ohov <
[email protected]>
Koopia: Triin Uusberg <
[email protected]>; SM Info <
[email protected]>;
<
[email protected]>; <
[email protected]>; REINAP, Marge <
[email protected]>;
BEN MAMOU, Myriam Corinne <
[email protected]>
Teema: Request for nomination: Technical consultation on measles and rubella
Manused: MRLabCons_ProvisionalAgenda_Nov2019.pdf;
MRLab_TechCons_Scope&Purpose.pdf; Estonia.pdf
Please see the attached correspondence sent from the World Health Organization, Regional Office for
Europe. One or more attachments may be included.
Veuillez vous référer à la correspondance ci-jointe du Bureau régional de l'Europe de l'Organisation
mondiale de la santé. Une ou plusieurs annexes peuvent être jointes.
Mit der Bitte um Kenntnisnahme der beiliegenden Korrespondenz (eine oder mehrere Anlagen),
Weltgesundheitsorganisation, Regionalbüro für Europa.
См. прикрепленные письма от Европейского регионального бюро Всемирной организации
здравоохранения (один или несколько прикрепленных файлов).
Saatja: Biviano, Florencia <
[email protected]>
Saaja: Elen Ohov, Triin Uusberg, SM Info,
[email protected],
[email protected], REINAP, Marge, BEN MAMOU, Myriam Corinne
Teema: RE: Technical consultation on Measles and Rubella- Copenhagen, 14-15 November
Dear Ms Ohov,
With reference to the attached letter, sent on September 27, I would like to apologize for addressing this request to you, as the letter was intended to be sent directly to the head of the WHO National Measles and Rubella reference laboratory in Estonia, invited to attend the meeting of the subject as an observer.
No action is required from your end.
We hope this letter has not caused any inconvenience.
Best regards,
Florencia Biviano
Programme Assistant
Vaccine-preventable Diseases & Immunization (VPI)
Division of Health Emergencies and Communicable Diseases (DEC)
World Health Organization Regional Office for Europe
UN City
Marmorvej 51, DK-2100 Copenhagen Ø, Denmark
Tel.: +45 45 33 70 38 Fax.: +45 45 33 70 01
[email protected]<mailto:
[email protected]> | www.euro.who.int/vaccines<http://www.euro.who.int/vaccine>
[cid:
[email protected]]
From: Biviano, Florencia
Sent: Friday, September 27, 2019 11:46
To:
[email protected]
Cc:
[email protected];
[email protected];
[email protected];
[email protected]; REINAP, Marge <
[email protected]>; Ben Mamou, Myriam Corinne <
[email protected]>
Subject: Estonia
Please see the attached correspondence sent from the World Health Organization, Regional Office for Europe. One or more attachments may be included.
Veuillez vous référer à la correspondance ci-jointe du Bureau régional de l'Europe de l'Organisation mondiale de la santé. Une ou plusieurs annexes peuvent être jointes.
Mit der Bitte um Kenntnisnahme der beiliegenden Korrespondenz (eine oder mehrere Anlagen), Weltgesundheitsorganisation, Regionalbüro für Europa.
См. прикрепленные письма от Европейского регионального бюро Всемирной организации здравоохранения (один или несколько прикрепленных файлов).
WORLD HEALTH ORGANIZATION ORGANISATION MONDIALE DE LA SANTÉ
REGIONAL OFFICE FOR EUROPE BUREAU RÉGIONAL DE L'EUROPE
WELTGESUNDHEITSORGANISATION ВСЕМИРНАЯ ОРГАНИЗАЦИЯ ЗДРАВООХРАНЕНИЯ
REGIONALBÜRO FÜR EUROPA ЕВРОПЕЙСКОЕ РЕГИОНАЛЬНОЕ БЮРО
Technical consultation for establishing /2
oversight mechanisms for measles and
rubella testing laboratories
UN City, Copenhagen, Denmark 09 September 2019
14-15 November 2019 Original: English
Scope and purpose
Background
The elimination of measles and rubella (MR) is one of the six goals of the European Vaccine
Action Plan 2015-2020 (EVAP) and a regional priority as agreed by all Member States in the
resolution of the WHO Regional Committee (EUR / RC64 / R5). The mid-term review of the
Global Strategic Plan for Measles and Rubella 2012-2020 emphasizes that high-quality,
comprehensive epidemiological surveillance of disease cases, carried out with the support of
laboratory services, is essential for successful disease monitoring and evaluation of country
efforts to ensure progress.
The WHO Regional Office for Europe (Regional Office) coordinates the European laboratory
network of measles and rubella laboratories (MR LabNet) comprising 69 subnational and
national reference laboratories in 50 of the Region's 53 Member States, 3 regional reference
laboratories (RRLs) in Luxembourg, Berlin, and Moscow and a global specialized laboratory
(GSL) in London.
WHO sustains the high proficiency of this network through periodic regional meetings, regular
dissemination of technical updates, training sessions and an annual accreditation programme.
The latter consists of external quality assessments and a desk-review of laboratory
performance data, together with periodic laboratory onsite audits by the WHO coordinator
and/or RRL/GSL senior experts.
In some Member States measles- and rubella-laboratory-supported surveillance is often
performed in non-WHO-accredited laboratories. This necessitates that mechanisms be in place
to guarantee the high quality and reliability of data originating from these laboratories, as
outlined in the Framework for the verification process of measles and rubella elimination in the
WHO European Region1. Additionally, as disease elimination progresses, the predictive value of
1
WHO, Eliminating measles and rubella. Framework for the verification process in the WHO European Region,
2014; http://www.euro.who.int/__data/assets/pdf_file/0009/247356/Eliminating-measles-and-rubella-Framework-for-the-
verification-process-in-the-WHO-European-Region.pdf
Scope and purpose
page 2
serological testing decreases, requiring more complex laboratory testing algorithm flowcharts,
as detailed in the Manual for the laboratory-based surveillance of measles, rubella, and
congenital rubella syndrome 2 and the Vaccine-preventable disease surveillance standards3.
Moreover, as advanced molecular techniques become widely available also in the private
sector, there is a tendency to incorrectly discard measles or rubella cases based solely on
negative results of molecular detection, thereby not adhering to WHO recommendations.
It is therefore crucial to ensure the proficiency of non-WHO-accredited laboratories involved in
MR laboratory-supported surveillance by strengthening the role of national MR laboratories in
overseeing their performance. Supported by their health authorities, some WHO-accredited
national laboratories have undertaken different approaches in the Region ranging from
conducting limited periodic quality control to establishing and coordinating fully-fledged
national laboratory networks with a comprehensive accreditation system aligned with that of
WHO. Conversely, several Member States still fail to provide information about the proficiency
of their non-WHO-accredited laboratories that test for MR, raising issues in assessing the
annual status updates provided by national verification committees (NVCs) to the Regional
Verification Commission for Measles and Rubella Elimination (RVC).
We propose a technical consultation with selected country delegations to review current
experiences in managing and documenting the proficiency of non-WHO-accredited MR
laboratories, discuss the options for sustainable oversight mechanisms by WHO national
reference laboratories, foster collaboration and inspiration among Member States and provide
technical support as appropriate.
Aim
To support Member States in establishing national measles and rubella Laboratory networks
and/or oversight mechanisms compliant with WHO MR LabNet standards to optimize their
contribution to the regional verification process of measles and rubella elimination.
Objectives
- Update the participants on WHO MR LabNet standards and new developments in MR
testing.
- Present MR elimination verification requirements and the role of the WHO-accredited
national laboratories.
- Provide a forum to exchange regional experiences, in particular, successful country
experiences and challenges in setting up national lab networks and/or oversight
mechanisms.
- Engage Member States to design country workplans.
2
WHO, Manual for the laboratory-based surveillance of measles, rubella, and congenital rubella syndrome,
Third edition, June 2018 https://www.who.int/immunization/monitoring_surveillance/burden/laboratory/manual/en/
3
WHO, Vaccine-reventable disease surveillance standards, October 2018,
https://www.who.int/immunization/monitoring_surveillance/burden/vpd/standards/en/
Scope and purpose
page 3
Deliverables
- Country workplans for establishing national networks and/or oversight mechanisms in
selected Member States (including preliminary monitoring and evaluation indicators and
costing estimates).
- Operational recommendations to Member States and to the Regional Office for the
implementation of country workplans.
- Meeting report.
Participants
- Country delegations from France, Germany, Israel, Italy, Poland, Romania and Spain, to
include representatives of WHO national measles and rubella reference laboratories, MR
surveillance system and ministries of health,
- Senior laboratory experts from the regional reference laboratory in Berlin and the Global
and Specialized Laboratory in London,
- RVC representative,
- Staff of the Regional Office involved in MR surveillance (epidemiologists, laboratory
coordinator) and in supporting the verification process,
- WHO headquarters representative,
- Observers from the European Centre for Disease Prevention and Control and the MR
National Laboratory of Estonia.
WORLD HEALTH ORGANIZATION ORGANISATION MONDIALE DE LA SANTÉ
REGIONAL OFFICE FOR EUROPE BUREAU RÉGIONAL DE L'EUROPE
WELTGESUNDHEITSORGANISATION ВСЕМИРНАЯ ОРГАНИЗАЦИЯ ЗДРАВООХРАНЕНИЯ
REGIONALBÜRO FÜR EUROPA ЕВРОПЕЙСКОЕ РЕГИОНАЛЬНОЕ БЮРО
Technical consultation for establishing /3
oversight mechanisms for measles and
rubella testing laboratories
UN City, Copenhagen 16 September 2019
14-15 November 2019 Original: English
Provisional agenda
1. Opening session
2. Regional WHO updates:
• Status of measles and rubella elimination in the WHO European Region,
• The European measles and rubella laboratory network
3. Rationale of establishing national measles-rubella Laboratory networks and/or oversight
mechanisms
4. Country experience: France, Germany, Israel, Italy, Poland, Romania and Spain
5. Designing country roadmaps / action plans
6. Recommendations and follow-up
7. Closure